Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

No Evidence for the Pathogenicity of the BRCA2 c.6937 + 594T>G Deep Intronic Variant: A Case-Control Analysis.

Dutil J, Godoy L, Rivera-Lugo R, Arroyo N, Albino E, Negrón L, Monteiro AN, Matta JL, Echenique M.

Genet Test Mol Biomarkers. 2018 Feb;22(2):85-89. doi: 10.1089/gtmb.2017.0187. Epub 2018 Jan 22.

PMID:
29356578
2.

Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family.

Palmirotta R, Lovero D, Stucci LS, Silvestris E, Quaresmini D, Cardascia A, Silvestris F.

Int J Mol Sci. 2018 Jan 18;19(1). pii: E285. doi: 10.3390/ijms19010285.

3.

Reproductive factors as risk modifiers of breast cancer in BRCA mutation carriers and high-risk non-carriers.

Park B, Hopper JL, Win AK, Dowty JG, Sung HK, Ahn C, Kim SW, Lee MH, Lee J, Lee JW, Kang E, Yu JH, Kim KS, Moon BI, Han W, Noh DY, Park SK; KOHBRA Study Group.

Oncotarget. 2017 Oct 31;8(60):102110-102118. doi: 10.18632/oncotarget.22193. eCollection 2017 Nov 24.

4.

Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study.

Mella S, Muzzatti B, Dolcetti R, Annunziata MA.

Hered Cancer Clin Pract. 2017 Oct 2;15:16. doi: 10.1186/s13053-017-0077-6. eCollection 2017.

5.

Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.

Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.

J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.

6.

Developing a risk prediction model for breast cancer: a Statistical Utility to Determine Affinity of Neoplasm (SUDAN-CA Breast).

Salih AM, Alam-Elhuda DM, Alfaki MM, Yousif AE, Nouradyem MM.

Eur J Med Res. 2017 Sep 29;22(1):35. doi: 10.1186/s40001-017-0277-6.

7.

Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.

Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E.

BMC Cancer. 2017 Jun 21;17(1):438. doi: 10.1186/s12885-017-3422-2.

8.

Treatment related toxicity in BRCA1-associated epithelial ovarian cancer - is DNA repairing impairment associated with more adverse events?

Badora-Rybicka A, Budryk M, Nowara E, Starzyczny-Słota D.

Contemp Oncol (Pozn). 2016;20(5):381-384. doi: 10.5114/wo.2016.64597. Epub 2016 Dec 20.

9.

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.

Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A.

Prz Menopauzalny. 2016 Dec;15(4):215-219. doi: 10.5114/pm.2016.65667. Epub 2017 Feb 8. Review.

10.

Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study.

Lai KN, Ho WK, Kang IN, Kang PC, Phuah SY, Mariapun S, Yip CH, Mohd Taib NA, Teo SH.

BMC Cancer. 2017 Feb 22;17(1):149. doi: 10.1186/s12885-017-3099-6.

11.

Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients.

Park B, Sohn JY, Yoon KA, Lee KS, Cho EH, Lim MC, Yang MJ, Park SJ, Lee MH, Lee SY, Chang YJ, Lee DO, Kong SY, Lee ES.

Breast Cancer Res Treat. 2017 May;163(1):139-150. doi: 10.1007/s10549-017-4142-7. Epub 2017 Feb 15.

12.

Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.

Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, Pal T.

Cancer. 2017 Jul 1;123(13):2497-2505. doi: 10.1002/cncr.30621. Epub 2017 Feb 9.

PMID:
28182268
13.

Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls.

Park JS, Nam EJ, Park HS, Han JW, Lee JY, Kim J, Kim TI, Lee ST.

Cancer Res Treat. 2017 Oct;49(4):1012-1021. doi: 10.4143/crt.2016.433. Epub 2017 Jan 17.

14.

Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.

Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, LaDuca H.

Breast Cancer Res Treat. 2017 Feb;161(3):575-586. doi: 10.1007/s10549-016-4085-4. Epub 2016 Dec 22.

15.

Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.

Chao A, Chang TC, Lapke N, Jung SM, Chi P, Chen CH, Yang LY, Lin CT, Huang HJ, Chou HH, Liou JD, Chen SJ, Wang TH, Lai CH.

Oncotarget. 2016 Dec 20;7(51):85529-85541. doi: 10.18632/oncotarget.13456.

16.

Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.

Evans DG, Woodward ER, Howell SJ, Verhoef S, Howell A, Lalloo F.

Fam Cancer. 2017 Apr;16(2):173-179. doi: 10.1007/s10689-016-9942-0.

17.

Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.

Fernandes GC, Michelli RA, Galvão HC, Paula AE, Pereira R, Andrade CE, Felicio PS, Souza CP, Mendes DR, Volc S, Berardinelli GN, Grasel RS, Sabato CS, Viana DV, Mauad EC, Scapulatempo-Neto C, Arun B, Reis RM, Palmero EI.

Oncotarget. 2016 Dec 6;7(49):80465-80481. doi: 10.18632/oncotarget.12610.

18.

Effective Referral of Low-Income Women at Risk for Hereditary Breast and Ovarian Cancer to Genetic Counseling: A Randomized Delayed Intervention Control Trial.

Pasick RJ, Joseph G, Stewart S, Kaplan C, Lee R, Luce J, Davis S, Marquez T, Nguyen T, Guerra C.

Am J Public Health. 2016 Oct;106(10):1842-8. doi: 10.2105/AJPH.2016.303312. Epub 2016 Aug 23.

19.

New challenges for BRCA testing: a view from the diagnostic laboratory.

Wallace AJ.

Eur J Hum Genet. 2016 Sep;24 Suppl 1:S10-8. doi: 10.1038/ejhg.2016.94. Review.

20.

Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients.

Eoh KJ, Park HS, Park JS, Lee ST, Han J, Lee JY, Kim SW, Kim S, Kim YT, Nam EJ.

Cancer Res Treat. 2017 Apr;49(2):408-415. doi: 10.4143/crt.2016.135. Epub 2016 Jul 27.

Supplemental Content

Support Center